Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q3 '26

Reports: Aug 17After Hours

Estimated EPS

-$0.08

Estimated Rev

---

$AVXL Q1 '26 Earnings Results & Recap Anavex anticipates, at its current cash utilization rate, an approximate cash runway of more than 3 years, supporting its ongoing clinical pipeline development.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.08
--
--
N/A
Q2 '26
-$0.07
-$0.06
14.29%
BEAT
Q1 '26
-$0.12
-$0.06
51.35%
BEAT
Q4 '25
-$0.15
-$0.11
26.67%
BEAT
Q3 '25
-$0.14
-$0.16
-12.41%
MISSED

Advertisement|Remove ads.